Global Pharmaceuticals Awards Grant to Myasthenia Gravis Alliance
November 24 2009 - 9:30AM
Business Wire
Global Pharmaceuticals, the generic products division of Impax
Laboratories, Inc. (NASDAQ: IPXL), today announced their
cooperation in awarding a modest grant to Myasthenia Gravis
Alliance, also known as Myasthenia Gravis Foundation of Greater New
York, Inc., a 501(3)(c) non profit membership corporation,
incorporated in the State of New York. A portion of the grant will
fund The Alliance Fellowship for Myasthenia Gravis Research, at the
University of California, Davis, under the direction of Dr. Robert
Fairclough, Faculty Researcher/ Principal Investigator. The
remainder of the grant will help defer the cost of The Circle News
and other operating items.
Myasthenia Gravis is a chronic, sometimes fatal autoimmune
neuromuscular disease in which communication between nerve and
muscle is impaired, causing muscle fatigue. The disease is highly
misdiagnosed. A neurologist is recommended for diagnosis. Global
Pharmaceuticals is a leading distributor of pyridostigmine bromide,
a key agent used in the treatment of Myasthenia Gravis.
Christopher Mengler, R.Ph., divisional president of Global
Pharmaceuticals said: “We are pleased to assist the Myasthenia
Gravis Alliance with a grant to further research and awareness of
this disease. We recognize the need for research that will
hopefully lead to improved quality of life and eventually result in
a cure.”
“Our primary goal is to ensure that the proper and appropriate
information is forwarded to our myasthenic patients as soon as they
are diagnosed,” Executive Director, Debra Santulli-Barone declared,
“since the first two years of diagnosis is crucial.”
Ms. Santulli-Barone continued: “I am so grateful to Global
Pharmaceuticals for listening to our needs and providing a grant.
This will give our members newfound hope. We can now launch a
monthly MG Series Support Meeting to address topics such as, 'How
to Deal with Your Spouse/Family While Living with MG, Cold Weather
Tips, and, Your Options with Medication.'”
About Myasthenia Gravis Alliance
Myasthenia Gravis Alliance has been a staple in the myasthenic
community for over 20 years. The charitable nonprofit organization
was formed to serve patient needs, promote public awareness,
provide support for patients, while continuing to fund research
when possible.
Myasthenia Gravis Alliance; Myasthenia Gravis Foundation of
Greater New York, Inc. (www.MGdirect.org) meetings will be held at
61 Gramercy Park North, Ste. 605, New York, NY 10010. For further
information, call Debra Santulli-Barone at (212) 533-7005.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded
products. Impax markets its generic products through its Global
Pharmaceuticals division and markets its branded products through
the Impax Pharmaceuticals division. Additionally, where
strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a
full range of capabilities in its Hayward and Philadelphia
facilities. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6107428&lang=en
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024